Hospital

Danielle DiBari, the chief pharmacy officer and senior vice president of business operations for NYC Health + Hospitals, discusses some of the challenges involved in coordinating vaccine distribution across New York’s public health system.

The oral, next-generation vascular endothelial growth factor tyrosine kinase inhibitor is the first therapy approved for this patient population following 2 or more prior systemic therapies.

Debu Tripathy, MD, University of Texas, MD Anderson Cancer Center at Houston, discussed the basic requirements of personalizing therapy.

An ongoing phase 2 clinical study has begun to vaccinate patients with a modified version of Moderna’s COVID-19 vaccine.

Study finds cancer survivors were 42% more likely to report walking at the slowest pace and had a 24% greater risk of mobility disability compared to individuals who never had cancer.

A recent survey showed that there is a significant preference among Americans to receive COVID-19 vaccines from a trusted health care provider, such as a pharmacist or physician.

Dwight Kloth, PharmD, FCCP, BCOP, director of pharmacy at Fox Chase Cancer Center, discusses the role of the oncology pharmacist in the cancer care continuum, and how this role has been impacted by the COVID-19 pandemic.

The additional COVID-19 doses will provide a buffer in addition to the already procured vaccines, and will also allow experts to plan for the later part of 2021, according to a White House briefing.

When applied as a filler for soft tissue defects and voids, the regenerative tissue filler shows promise for accelerating and improving tissue restoration outcomes.

The study authors also mention that samples taken from skin biopsies confirmed their suspicion of a delayed allergic immune response that is commonly seen in drug reactions.

Notably, the United States has now administered the most first-shot COVID-19 vaccinations of any country, with 82.6 million.

Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.

The FDA has issued an emergency use authorization (EUA) for a COVID-19 diagnostic test that can confirm recent or prior COVID-19 infection.

Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the behaviors that cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.

The guidance said relaxing certain measures for vaccinated individuals may help improve COVID-19 vaccine acceptance and uptake.

Women who attended the 2 more recent screenings prior to their breast cancer diagnosis had a 50% lower incidence of their cancer being fatal within 10 years.

Study findings demonstrate the importance of interventions for multiple sclerosis therapy, such as those supporting medication adherence, adverse effect management, symptom management, and additional counseling.

The FDA has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

New protein-based immunotherapies could stimulate patients’ immune systems without needing to engineer T cells on an individual basis.

Investigators are set to begin testing sulfasalazine and auronofin, which are FDA-approved to treat rheumatoid arthritis, in cancer cell models.

The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

The first vaccine dose alone offered strong protection against COVID-19, with efficacy that did not decline over the 3 months between doses.

President Joseph Biden announced a partnership between Merck and Johnson & Johnson, in which 2 of Merck’s facilities will begin producing the Johnson & Johnson COVID-19 vaccine.

COVID-19 is fueling the expansion of treatment methods beyond medications to include digital therapeutics.

Although there have been many challenges and concerns during the pandemic, experts said there are also lessons to be learned and implemented once the pandemic is over.

Investigators recommended avoiding risk factors such as smoking and switching to a transdermal administration route for testosterone.

Results show respondents' top drivers of happiness in the workplace are colleagues, compensation, and autonomy.

View the full results from the Pharmacy Times 2020 Salary and Job Satisfaction Survey.